Market Overview

UPDATE: Jefferies Raises PT on Regeneron Pharmaceuticals Following Top-Line Q1 Beat

Share:
Related REGN
The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering
Earnings Scheduled For November 6, 2018
ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q3 2018 (Seeking Alpha)

In a report published Monday, Jefferies analyst Biren Arnin reiterated a Hold rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $179.00 to $247.00.

In the report, Arnin noted, “REGN reported a top-line beat driven by U.S. Eylea sales leading to slightly raised guidance. Given the recent strength in REGN shares attributed to Avastin cmpding issues, there appeared to be very little shift away from Avastin. We have, however, raised our PT to $247 largely due to increased traction in ex-U.S. Eylea sales and the value for PIII alirocumab for hypercholesterolemia.”

Regeneron Pharmaceuticals closed on Friday at $248.63.

Latest Ratings for REGN

DateFirmActionFromTo
Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Oct 2018Canaccord GenuityMaintainsHoldHold
Oct 2018Cantor FitzgeraldInitiates Coverage OnNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
XECImperial CapitalDowngrades35.0
SSTIImperial CapitalUpgrades49.0
AVDLoop CapitalUpgrades29.0
FCREYDeutsche BankUpgrades0.0
OECUBSUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Week in FX Asia -Yen Bears Are Beginning To See The Light

UPDATE: Jefferies Raises PT on Cabot Oil & Gas on Free Cash Flow